BAY-474 is an inhibitor of tyrosine-protein kinase c-Met and can act as an epigenetics probe.
|Solubility (25°C)||DMSO 58 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related c-Met Products|
|Tepotinib Hydrochloride Hydrate
Tepotinib Hydrochloride Hydrate is a potent, selective c-Met inhibitor with an IC50 of 4 nM and is more than 200-fold more selective for c-Met than for IRAK4, TrkA, Axl, IRAK1 and Mer.
Capmatinib hydrochloride is a potent, orally active, selective, ATP-competitive c-Met kinase inhibitor that inhibits the phosphorylation of c-MET and downstream effector proteins of the c-MET pathway, with an IC50 value of 0.13 nM. In addition, Capmatinib hydrochloride In addition, Capmatinib hydrochloride can inhibit the proliferation and migration of c-Met-dependent tumor cells, and can effectively induce apoptosis (apoptosis), with anti-tumor activity.
MET kinase-IN-4 is an orally active Met kinase inhibitor. MET kinase-IN-4 has potent Met kinase inhibitory activity with an IC50 value of 1.9 nM. MET kinase-IN-4 can be used for the research of cancer.
Boditrectinib oxalate is a potent tyrosine kinase inhibitor. Boditrectinib oxalate serves as an antineoplastic agent. Boditrectinib oxalate is useful in the research of cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
Adrixetinib is an inhibitor of protein tyrosine kinase with antineoplastic activity.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.